… in SLE. In the current review, we cover the actual knowledge on IFNs and other studied
cytokines as biomarkers and treatment targets in SLE. … and therapeutic target for SLE [10,13]. …

… therapeutic targets show potential. In this review, we will discuss emerging new SLE therapeutic
targets in … cytokine could potentially be a therapeutic target in SLE. BAFF and APRIL as …

… the expression of inflammatory chemokines and cytokines by activating the late mitogen-…
participate in the development of SLE, thus providing a potential therapeutic target for SLE (37). …

… This review describes recent data from genetic analyses of patients with SLE, along with …
mechanisms, identify therapeutic targets and stimulate development of therapeutics that can …

… of SLE. We also summarize the therapeutic application of B cell-derived autoantibody in
SLE. … cell clearance will result in impaired tolerance and altered cytokine expression [20]. …

… may also reflect type II and III interferon activity, and assessment of IFN cytokine levels in
future … is a viable therapeutic target that reduces disease activity in patients with SLE and other …

Systemic lupus erythematosus (SLE) is a multifactorial chronic autoimmune disease, marked
by the presence of autoantibodies to nuclear antigens belonging to different isotype classes…

… has been implicated in SLE, offering a possible therapeutic target [47]… cytokines signal
through the Janus kinase (JAK) pathways, making the latter an attractive therapeutic target in SLE […

… cytokine BAFF (B cell activating factor), as the first Food and Drug Administration (FDA)-approved
therapy for human SLE in the … clinical efficacy of belimumab in SLE is relatively modest. …

… in anti-IFN-α treatments in systemic lupus erythematosus (SLE), primary Sjögren syndrome
(… target cytokine, thus normalizing the expression of type I IFN-inducible genes, as therapeutic …